Treatment of Pseudomonas mendocina Infection
Treat Pseudomonas mendocina infections with third or fourth generation cephalosporins (ceftriaxone, cefepime, or ceftazidime) or fluoroquinolones as first-line therapy, based on antimicrobial susceptibility testing. 1
Antimicrobial Selection
P. mendocina has a distinctly different and more favorable antimicrobial susceptibility profile compared to P. aeruginosa, with susceptibility to most antibiotics tested and fewer known resistances 2. This is a critical distinction—do not automatically assume the same resistance patterns as P. aeruginosa.
First-Line Options:
- Third-generation cephalosporins: Ceftriaxone has been successfully used in documented cases 3, 4
- Fourth-generation cephalosporins: Cefepime and ceftazidime are effective alternatives 3
- Fluoroquinolones: Effective when susceptible, though resistance has been documented 3
Important Caveat on Fluoroquinolone Resistance:
Recent case reports demonstrate emerging fluoroquinolone resistance in P. mendocina 3. Always obtain susceptibility testing before relying on quinolones, particularly in immunocompromised patients.
Treatment Duration and Approach
For bacteremia/severe infections: 10-14 days of intravenous therapy 4
For urinary tract infections: 7 days of appropriate antibiotics 3
For skin and soft tissue infections: Standard duration based on clinical response 2
Clinical Context Matters
High-Risk Populations:
P. mendocina causes severe infections predominantly in:
- Immunocompromised patients (HIV/AIDS, cancer patients on chemotherapy) 3, 4
- Patients with diabetes and vascular disease 2
- Those with breached skin barriers (cellulitis, wounds) 2
Common Infection Types:
- Infective endocarditis (most severe presentation)
- Bacteremia/sepsis
- Central nervous system infections
- Skin and soft tissue infections
- Urinary tract infections (rare but documented) 3, 1
Key Management Principles
Always obtain blood cultures in febrile patients with risk factors, as sepsis occurs in nearly half of documented cases 1
De-escalate therapy based on susceptibility results—unlike P. aeruginosa, P. mendocina often allows for narrower spectrum coverage 4
Monitor for sepsis: Fever is the predominant presenting symptom, and septic presentations are common despite the organism's rarity 1
Consider environmental sources: P. mendocina lives in soil and water; contamination through skin barrier disruption is the typical route 2
Prognosis
Mortality is low across all infection types when appropriate antibiotics are administered 1. All 14 documented cases in the literature prior to 2019 resulted in successful treatment and patient survival 4. This favorable outcome distinguishes P. mendocina from its more notorious relative, P. aeruginosa.
Critical Pitfall to Avoid
Do not treat P. mendocina empirically as multidrug-resistant P. aeruginosa. While guidelines for carbapenem-resistant Pseudomonas aeruginosa recommend newer agents like ceftolozane-tazobactam or ceftazidime-avibactam 5, these are unnecessary for P. mendocina, which typically responds to standard antipseudomonal agents. Overtreatment wastes resources and promotes resistance.